Skin side effects of inflammatory bowel disease therapy

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages 1086-1098

  Torres, Joana ^a   Buche, Sébastien ^b   Delaporte, Emmanuel ^b   Colombel, Jean Frédéric ^c  

^a HOSPITAL BEATRIZ ÂNGELO   (Portugal)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

IBD; Non melanoma skin cancer; Psoriasis; Side effects

Indexed keywords

ACICLOVIR; ADALIMUMAB; CIPROFLOXACIN; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; STEROID; TUMOR NECROSIS FACTOR ALPHA; VALACICLOVIR; CERTOLIZUMAB PEGOL; FAMCICLOVIR; SUNSCREEN; TUMOR NECROSIS FACTOR INHIBITOR;

ACNE; ADVERSE OUTCOME; ALGORITHM; ALOPECIA; APHTHOUS STOMATITIS; CANCER RISK; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ENTERITIS; ERYTHEMA; FLUSHING; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTRICHOSIS; INJECTION SITE DISCOLORATION; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; NON MELANOMA SKIN CANCER; PATHOGENESIS; PATIENT COUNSELING; PRIORITY JOURNAL; PSORIASIS; PURPURA; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SKIN MANIFESTATION; SKIN REDNESS; SKIN THINNING; STEVENS JOHNSON SYNDROME; STRIA; TOXIC EPIDERMAL NECROLYSIS; ULCERATIVE COLITIS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VIRUS INFECTION; ALOPECIA AREATA; ATOPIC DERMATITIS; BACTERIAL SKIN DISEASE; BASAL CELL CARCINOMA; CANCER EPIDEMIOLOGY; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; DRUG HYPERSENSITIVITY; ERYTHEMA MULTIFORME; GENITAL HERPES; GRANULOMATOUS INFLAMMATION; HIGH RISK PATIENT; LICHENOID; MELANOMA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PUSTULOSIS PALMOPLANTARIS; RED MAN SYNDROME; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SKIN CARCINOGENESIS; SKIN LYMPHOMA; SKIN PROTECTION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; ULTRAVIOLET RADIATION; VARICELLA ZOSTER VIRUS; VASCULITIS; VIRAL SKIN DISEASE; VITILIGO;

DRUG ERUPTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; SKIN DISEASES;

EID: 84876399144     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182802c07     Document Type: Review

References (66)

1. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008;64:753-767.
2. de Fonclare A, Khosrotehrani K, Aractingi S, et al. Erythema nodosumlike eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch Dermatol. 2007;143:744-748.
3. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
4. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91.
5. Guy GPJ, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics. 2011;29:863-874.
6. Alam M, Ratner D.Cutaneous squamous-cell carcinoma. New Engl J Med. 2001;344:975-983.
7. Lindelof B, Sigurgeirsson B, Gabel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143: 513-519.
8. Brem R, Li F, Karran P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res. 2009;37:1951-1961.
9. Attard NR, Karran P. UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochem Photobiol Sci. 2012; 11:62-68.
10. Lohmann CM, Solomon AR. Clinicopathologic variants of cutaneous squamous cell carcinoma. Adv Anat Pathol. 2001;8:27-36.
11. Stoff B, Salisbury C, Parker D, et al. Dermatopathology of skin cancer in solid organ transplant recipients. Transpl Rev (Orlando). 2010;24:172- 189.
12. Zaravinos A, Kanellou P, Spandidos DA. Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Dermatol. 2010;162:325-331.
13. Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study. Int J Epidemiol. 2006; 35:1514-1521.
14. Bangash HK, Colegio OR. Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr Treat Options Oncol. 2012;13:354-376.
15. Gjersvik P, Hansen S, Møller BL, et al. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients? Transpl Int. 2000;13:S380-S381.
16. Fogo AJ, Hunt JB, Clement M. Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-a. Clin Exp Dermatol. 2010;35: 793-795.
17. Nancey S, Boschetti G, Cotte E, et al. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab. Inflamm Bowel Dis. 2011;17: 1060-1061.
18. Long MD, Martin C, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-399.
19. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105:1480-1487.
20. Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141:1612-1620.
21. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268-274.
22. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1612-1628. e1-5.
23. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010;105:1604-1609.
24. Setshedi M, Epstein D, Winter TA, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of nonmelanoma skin cancer in an at-risk population: A cohort study. J Gastroenterol Hepatol. 2012;27:385-389.
25. van Schaik FD, van Oijen MG, Smeets HM, et al. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol. 2011;449-450. e1;author reply 50-51.
26. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:194-198.
27. Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl. 2009;9(suppl 3):S1-S155.
28. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factoralpha antagonists. Br J Dermatol. 2007;156:486-491.
29. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666-R676.
30. Cleynen I, Van Moerkercke M, Juergens M, et al. Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut. 2010;59:A1.
31. Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009; 102:1133-1140.
32. Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486-504.
33. Hawryluk EB, Linskey KR, Duncan LM, et al. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012;39:481-492.
34. Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am. 2006;35:857-866.
35. US FDA. Tumor Necrosis Factor Alpha (TNF-a) Antagonists: Serious Skin Reactions. FDA Drug Safety Newsletter. Postmarketing Reviews - 1(2):Winter 2008. Available at: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ ucm119034.htm#tnf. Accessed June 20, 2012.
36. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol. 2009;15: 4449-4452.
37. Mounach A, Rezqi A, Nouijai A, et al. Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. 2012;55:436-439.
38. Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:91-98.
39. Subramanian S, Yajnik V, Sands BE, et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis. 2011;17: 99-104.
40. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-128.
41. Verea MM, Del Pozo J, Yebra-Pimentel MT, et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother. 2004;38:54-57.
42. Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti- TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518-523.
43. Passarini B, Infusino SD, Barbieri E, et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by antitumor- necrosis-factor antibody therapy. Dermatology. 2007;215:295-300.
44. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055.
45. Steinwurz F, Denadai R, Saad-Hossne R, et al. Infliximab-induced psoriasis during therapy for Crohn's disease. J Crohns Colitis. 2012;6:610- 616.
46. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318-1327.
47. Afzali A, Wheat C, Lee S. The association of psoriasis with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease. Abstracts from the 2011 Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation's National Clinical & Research Conference December 2011. IBD. 2011;17:S1-S100.
48. Buisson A, Cuny JF, Barbaud A, et al. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1175-1180.
49. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001.
50. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100-108.
51. Chowers Y, Sturm A, Sans M, et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohn's Colitis. 2010;4:367- 376.
52. Spencer JM, Silvers DN, Grossman ME. Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug eruption? Br J Dermatol. 1994;130:514-519.
53. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1:159-165.
54. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005; 202:135-143.
55. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by antitumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518.
56. Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921-927.
57. Cleynen I, Henckaerts L, Claes K, et al. M2064 development of psoriasiform skin lesions under anti-TNF therapy: a common link with IL23R gene variants? Gastroenterology. 2008;134:A-461.
58. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor a therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheuma Dis. 2009;68:209-215.
59. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827-836.
60. van der Heide F, Dijkstra A, Weersma RK, et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2009;15:1199-1207.
61. Mossner R, Thaci D, Mohr J, et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res. 2008;300:101-105.
62. Shale M, Ghosh S. Learning the lessons of antitumour necrosis factor therapy-associated psoriasis. Can J Gastroenterol. 2009;23:674-676.
63. Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed. 2011;27:186-189.
64. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheuma Dis. 2012;71:869- 874.
65. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130-2135.
66. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895-1904.